Cite
HARVARD Citation
Boilève, A. et al. (2021). Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. European journal of cancer. pp. 55-63. [Online].